The value of clopidogrel versus aspirin in reducing atherothrombotic events: The CAPRIE study

被引:21
作者
Durand-Zaleski, I
Bertrand, M
机构
[1] Assistance Publ Hop Paris, Henri Mondor Hosp, Publ Hlth Serv, Paris, France
[2] Hop Cardiol, Dept Cardiol, F-59037 Lille, France
关键词
D O I
10.2165/00019053-200422004-00005
中图分类号
F [经济];
学科分类号
02 ;
摘要
Atherothrombotic disease is a growing health problem, and is increasingly more costly to manage. Clopidogrel is an advanced, specific adenosine diphosphate receptor antagonist, which has been shown to be a highly potent antiplatelet agent. Data from the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) study have demonstrated the significantly superior clinical benefit of clopidogrel over aspirin for secondary prevention of atherothrombotic disease, with a relative risk reduction in myocardial infarction, stroke or vascular death of 8.7% (95% confidence interval 0.3, 16.5; P = 0.043). Moreover, clopidogrel demonstrated an amplified clinical benefit versus aspirin in patients at high risk of atherothrombotic events, such as those with a previous history of symptomatic atherothrombotic disease or with major risk factors such as diabetes mellitus or hypercholesterolaemia. On the basis of commonly accepted threshold criteria (EURO20000 per life-year gained; LYG), clopidogrel in comparison with aspirin is cost-effective for the secondary prevention of atherothrombotic disease (cost per LYG ranging from EURO19462 to EURO3256). Economic analyses have demonstrated consistent cost-effectiveness results with clopidogrel in different countries. Moreover, in high-risk patient subgroups the cost-effectiveness of clopidogrel in comparison with aspirin was even better (cost per LYG ranging from EURO5900 to EURO6310). Compared with other treatment strategies used for the prevention of ischaemic or atherothrombotic events, the cost-effectiveness of clopidogrel in comparison with aspirin based on CAPRIE is favourable, with most analyses in the intermediate range of cost-effectiveness. The available data thus support the use of clopidogrel as a clinically efficient and cost-effective option for secondary prevention of atherothrombotic disease, particularly in high-risk patients.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 35 条
[1]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[2]  
Annemans L, 2003, J MED ECON, V6, P55
[3]  
ANNEMANS L, 2003, VALUE HEALTH, V6, pCV6
[4]  
[Anonymous], 2000, Lancet, V355, P253, DOI DOI 10.1016/S0140-6736(99)12323-7
[5]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[6]   Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer [J].
Berthelot, JM ;
Will, BP ;
Evans, WK ;
Coyle, D ;
Earle, CC ;
Bordeleau, L .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1321-1329
[7]   Amplified benefit of Clopidogrel versus aspirin in patients with diabetes mellitus [J].
Bhatt, DL ;
Marso, SP ;
Hirsch, AT ;
Ringleb, PA ;
Hacke, W ;
Topol, EJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (06) :625-+
[8]  
Bhatt DL, 2001, CIRCULATION, V103, P363
[9]   Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin [J].
Bhatt, DL ;
Hirsch, AT ;
Ringleb, PA ;
Hacke, W ;
Topol, EJ .
AMERICAN HEART JOURNAL, 2000, 140 (01) :67-73
[10]  
BHATT DL, 2000, J AM COLL CARDIOL S, P906